GSK’s Nuvalent acquisition brings two lead programs, each addressing different targets for non-small cell lung cancer. The ...

The tumor microenvironment has emerged as a major regulator of cancer progression across solid tumors, but its influence is particularly pronounced in ...

INNMF READ THE FULL INNMF RESEARCH REPORT Amplia Therapeutics (OTCQB: INNMF) is a clinical-stage drug development company ...

Early results reveal how a single‑cell spatial platform maps stromal barriers that limit antibody delivery and target ...

PSMA PET has become central to prostate cancer imaging as advanced disease incidence rises and prostate-specific membrane ...

Eben Rosenthal, MD, the Barry and Amy Baker Professor and Chair of the Department of Otolaryngology-Head and Neck Surgery at Vanderbilt Health, is the senior author of the paper. Rosenthal and ...

Michael C. Heinrich, MD, discusses the eventual goal of using velzatinib as an early-line treatment for gastrointestinal stromal tumors. Michael C. Heinrich, MD, of Oregon Health and Science ...

Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Shorla Oncology for ...

A new research paper was published in Volume 17 of Oncotarget on May 20, 2026, titled “Microenvironmental CTHRC1 has a ...

For patients with a rare cancer that arises in the gut wall, standard treatment hasn’t changed in the last 20 years. At the American Society of Clinical Oncology meeting in Chicago, GSK shared a first ...

Cancer immunotherapy has entered a transformative era, providing durable benefits to many patients. However, a substantial subset of malignancies remains ...

Blood test shows potential for noninvasive monitoring of tumor microenvironment changes and emerging treatment resistance in ...